| Year |
Citation |
Score |
| 2017 |
Lourenco AP, Benson KL, Henderson MC, Silver M, Letsios E, Tran Q, Gordon KJ, Borman S, Corn C, Mulpuri R, Smith W, Alpers J, Costantini C, Rohatgi N, Yang R, et al. A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women Under the Age of 50 Years. Clinical Breast Cancer. PMID 28624156 DOI: 10.1016/J.Clbc.2017.05.004 |
0.395 |
|
| 2016 |
Henderson MC, Hollingsworth AB, Gordon K, Silver M, Mulpuri R, Letsios E, Reese DE. Integration of Serum Protein Biomarker and Tumor Associated Autoantibody Expression Data Increases the Ability of a Blood-Based Proteomic Assay to Identify Breast Cancer. Plos One. 11: e0157692. PMID 27508384 DOI: 10.1371/Journal.Pone.0157692 |
0.401 |
|
| 2009 |
Gordon KJ, Kirkbride KC, How T, Blobe GC. Bone morphogenetic proteins induce pancreatic cancer cell invasiveness through a Smad1-dependent mechanism that involves matrix metalloproteinase-2 Carcinogenesis. 30: 238-248. PMID 19056927 DOI: 10.1093/Carcin/Bgn274 |
0.572 |
|
| 2008 |
Gordon KJ, Blobe GC. Role of transforming growth factor-β superfamily signaling pathways in human disease Biochimica Et Biophysica Acta - Molecular Basis of Disease. 1782: 197-228. PMID 18313409 DOI: 10.1016/J.Bbadis.2008.01.006 |
0.598 |
|
| 2008 |
Gordon KJ, Dong M, Chislock EM, Fields TA, Blobe GC. Loss of type III transforming growth factor beta receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression. Carcinogenesis. 29: 252-62. PMID 17999987 DOI: 10.1093/Carcin/Bgm249 |
0.702 |
|
| 2007 |
Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, Kelly P, Moeller BJ, Marks JR, Blobe GC. The type III TGF-beta receptor suppresses breast cancer progression. The Journal of Clinical Investigation. 117: 206-17. PMID 17160136 DOI: 10.1172/Jci29293 |
0.572 |
|
| Show low-probability matches. |